Table 3. Comparison of respected large center series of NEO-OLT for CCA.
| Institution | Nebraska | Mayo | Emory |
|---|---|---|---|
| Composite radiation dose | 60 Gy (all given by LDR brachytherapy) | External beam (45 Gy) + LDR brachytherapy (20-30 Gy) | External beam (45 Gy) + HDR brachytherapy/VMAT/conventional EBRT boost (9-26.4 Gy) |
| Chemo | 5-FU | 5-FU | 5-FU or capecitabine |
| Number of patients enrolled in NEO-OLT | 17 | 131 | 10 |
| Number of transplanted Pts | 11 | 81 | 8 |
| TFS (%) | 82 | 92 | 100 |
| OS (%) | 45 | 72 | 75 |
| Median F/U | 7.5 years | 5 years | 2.27 years |
TFS, tumor-free survival; OS, overall survival; NEO, neoadjuvant; CCA, cholangiocarcinoma; VMAT, volumetric-modulated arc therapy; OLT, orthotopic liver transplantation; HDR, high dose rate; LDR, low dose rate; EBRT, external beam radiation therapy.